MD Anderson and Replay announce FDA clearance of IND application for first-in-class PRAME-targeted TCR NK cell therapy for hematological malignancies
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for PRAME TCR/IL-15 NK (SY-307), an engineered T cell receptor natural killer (TCR NK) cell therapy for relapsed/refractory myeloid malignancies. MD Anderson is the IND sponsor.
PRAME TCR/IL-15 NK (SY-307) is being developed...
MD Anderson and CureVac enter strategic collaboration to develop novel cancer vaccines
The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel...